DGAP-News

Evotec enters biology collaboration with Probiodrug - Seite 2

2 diabetes. Compounds and technology patents of its DP4 program in diabetes
were licensed to various pharmaceutical companies. In 2004, all metabolic
assets were sold to OSI Pharmaceuticals, Inc. The first drug based on
Probiodrug´s technologies reached the market in late 2006. Proceeds of the
various transactions have been reinvested by the Company to fund the novel
approach for the treatment of AD and inflammatory diseases.
The Company was founded in 1997 by Prof Dr Hans-Ulrich Demuth and Dr Konrad
Glund. Probiodrug has raised EUR71 m for its QC program. For more
information please visit www.probiodrug.de.

FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.

Contact Evotec AG:
Dr Mario Polywka, Chief Operating Officer, Phone: [phone],
[e-mail]

End of Corporate News

---

28.11.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP´s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language:    English                                                
Company:     Evotec AG                                              
             Manfred Eigen Campus / Essener Bogen 7                 
             22419 Hamburg                                          
             Germany                                                
Phone:       [phone]                                     
Fax:         [phone]                                   
E-mail:      [e-mail]                                        
Internet:    www.evotec.com                                         
ISIN:        DE0005664809                                           
WKN:         566480                                                 
Indices:     TecDAX                                                 
Listed:      Regulierter Markt in Frankfurt (Prime Standard);       
             Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,   
             München, Stuttgart                                     

End of News    DGAP News-Service  

---

  
194911 28.11.2012